Ardelyx (ARDX) Stock Price, News & Analysis

Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $5.06 to $5.73
• 50-Day Range: $4.58 to $6.42
• 52-Week Range: $4.32 to $9.83
• Volume: 3.98 million shs
• Average Volume: 4.35 million shs
• Market Capitalization: $1.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.93
• Consensus Rating: Buy

Ardelyx Stock Analysis - MarketRank™

Ardelyx scored higher than 88% of companies evaluated by MarketBeat, and ranked 237th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ardelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ardelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ardelyx are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ardelyx is -17.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ardelyx is -17.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ardelyx has a P/B Ratio of 7.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.24% of the outstanding shares of Ardelyx have been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Ardelyx has recently increased by 12.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardelyx does not currently pay a dividend.

Dividend Growth

Ardelyx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.32

Percentage of Shares Shorted

11.24% of the outstanding shares of Ardelyx have been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Ardelyx has recently increased by 12.74%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.53

News Sentiment

Ardelyx has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Ardelyx this week, compared to 9 articles on an average week.

Search Interest

28 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Ardelyx insiders have bought 179.93% more of their company's stock than they have sold. Specifically, they have bought $1,989,121.00 in company stock and sold $710,576.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Ardelyx is held by insiders.

Percentage Held by Institutions

58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARDX Stock Analysis - Frequently Asked Questions

How have ARDX shares performed this year?

Ardelyx's stock was trading at $5.07 on January 1st, 2025. Since then, ARDX stock has increased by 2.7% and is now trading at $5.2050.
View the best growth stocks for 2025 here.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its earnings results on Thursday, February, 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, hitting analysts' consensus estimates of $0.02. The biopharmaceutical company had revenue of $116.13 million for the quarter, compared to analyst estimates of $111.16 million. Ardelyx had a negative net margin of 28.82% and a negative trailing twelve-month return on equity of 46.60%.

Who are Ardelyx's major shareholders?

Top institutional shareholders of Ardelyx include Janus Henderson Group PLC (10.30%), Vanguard Group Inc. (6.06%), Geode Capital Management LLC (2.33%) and Millennium Management LLC (1.25%). Insiders that own company stock include Michael Raab, Susan Rodriguez, Robert Blanks, Elizabeth A Grammer, Laura A Williams, Justin A Renz, David P Rosenbaum and Robert Ora Felsch.
View institutional ownership trends.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), General Electric (GE), Builders FirstSource (BLDR) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 2/21/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARDX
• CUSIP: N/A
• CIK: 1437402
• Web: www.ardelyx.com
• Phone: (510) 745-1700
• Fax: 510-745-0493
• Employees: 90
• Year Founded: 2007

Price Target and Rating

• Average Stock Price Target: $9.42
• High Stock Price Target: $14.00
• Low Stock Price Target: $5.50
• Potential Upside/Downside: +64.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-66,070,000.00
• Net Margins: -28.82%
• Pretax Margin: -28.60%
• Return on Equity: -46.60%
• Return on Assets: -21.49%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 4.03
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: $124.46 million
• Price / Sales: 10.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 7.94

Miscellaneous

• Outstanding Shares: 236,850,000
• Free Float: 222,880,000
• Market Cap: $1.35 billion
• Optionable: Optionable
• Beta: 0.85